Alzheimer's & dementia : the journal of the Alzheimer's Association
-
Randomized Controlled Trial Multicenter Study
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
EXPEDITION and EXPEDITION2 were identically designed placebo-controlled phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding soluble amyloid-β peptide, on cognitive and functional decline over 80 weeks in patients with mild-to-moderate Alzheimer's disease (AD). Primary findings for both studies have been published. ⋯ These findings describe solanezumab effects on efficacy/safety measures in a mild AD population. Another phase 3 study, EXPEDITION3, will investigate solanezumab's effects in a mild AD population.